Tumor suppressor gene, p28ING5

• US 8,026,350 B2
• Filed: 08/27/2008
• Issued: 09/27/2011
• Est. Priority Date: 01/23/2002
• Status: Expired due to Fees

• Current Assignee: United States Department Of Health And Human Services (Government of the United States of America)
• Original Assignee: The United States of America As Represented By Thedepartment of Health and Human Services
• Inventors: Nagashima, Makoto, Pedeux, Remy, Shiseki, Masayuki, Harris, Curtis C.
• Primary Examiner(s): Yu; Misook
• Assistant Examiner(s): Halvorson; Mark
• Application Number:
  US12/198,897
• Publication Number:
  US 20090081779A1
• Time in Patent Office: 1,126 Days
• Field of Search: None
• US Class Current: 536/23.1
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/4703 Inhibitors; Suppressors
• CPC Class Codes: C12N 5/0693 Tumour cells; Cancer cells

Abstract

This disclosure provides a novel tumor suppressor, referred to as p28ING5, nucleic acid molecules encoding this protein, and methods of making and using these molecules. Also provided are methods of ameliorating, treating, detecting, prognosing, and diagnosing diseases and conditions associated with abnormal p28ING5 expression, such as neoplasia. Kits are also provided.

Claims

1. A recombinant polynucleotide encoding a p28ING5 tumor suppressor protein, wherein the recombinant polynucleotide consists of the nucleotide sequence of SEQ ID NO:

1.

2. A recombinant nucleic acid molecule comprising a promoter sequence operably linked to the recombinant polynucleotide of claim 1.

3. The recombinant nucleic acid molecule of claim 2, wherein the recombinant polynucleotide is in antisense orientation relative to the promoter sequence.

4. A recombinant vector comprising the recombinant nucleic acid molecule of claim 2.